-

10:27:20 PM

NVAX Stock News

NVAX - Novavax, Inc.

06/28/22 6:41 PM

Nasdaq : NVAX

covid-19high short

Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants

Novavax prototype vaccine (NVX-CoV2373) demonstrates broad immune responses including against Omicron and other circulating variants Pre-clinical data demonstrated that b oosting with Novavax' Omicron or prototype vaccine induces immune response against Omicron variants, including BA.4/5 Novavax

RHEA-AI

neutral

06/23/22 4:01 PM

Nasdaq : NVAX

covid-19high short

Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,

RHEA-AI

neutral

06/23/22 2:39 PM

Nasdaq : NVAX

covid-19high short

Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

Novavax, Inc. (Nasdaq: NVAX), a biotechnology

RHEA-AI

neutral

06/13/22 7:00 AM

Nasdaq : NVAX

covid-19high short

Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing

RHEA-AI

neutral

06/07/22 5:08 PM

Nasdaq : NVAX

covid-19high short

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine available in

RHEA-AI

neutral

05/09/22 4:02 PM

Nasdaq : NVAX

earningshigh short

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage company Reiterating full year 2022 total revenue guidance of between $4 and $5 billion Continued label expansion including primary, booster and adolescent authorizations

RHEA-AI

very positive

05/04/22 4:02 PM

Nasdaq : NVAX

conferenceshigh short

Novavax to Participate in BofA Securities 2022 Healthcare Conference

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in BofA Securities 2022 Healthcare Conference.

RHEA-AI

neutral

05/02/22 4:02 PM

Nasdaq : NVAX

conferencesearningshigh short

Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2022 financial results and operational

RHEA-AI

neutral

04/29/22 11:07 AM

Nasdaq : NVAX

covid-19high short

FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious

RHEA-AI

neutral

04/22/22 7:00 AM

Nasdaq : NVAX

clinical trialcovid-19high short

Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial

Novavax, Inc. (Nasdaq:

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

NVAX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.novavax.com
CeoStanley Erck
Security nameNovavax, Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees791
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address21 Firstfield Rd
StateMaryland
CityGaithersburg
Zip20878-1757
CountryUS
Phone12402682000

About Novavax, Inc.

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.